Last Updated: September 29, 2026

Details for New Drug Application (NDA): 207078

✉ Email this page to a colleague

NDA 207078 describes LOKELMA, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are fourteen patents protecting this drug. Additional details are available on the LOKELMA profile page.

The generic ingredient in LOKELMA is sodium zirconium cyclosilicate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium zirconium cyclosilicate profile page.

Summary for 207078

Tradename:	LOKELMA
Applicant:	Astrazeneca
Ingredient:	sodium zirconium cyclosilicate
Patents:	14

Suppliers and Packaging for NDA: 207078

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078	NDA	AstraZeneca Pharmaceuticals LP	0310-1105	0310-1105-30	30 PACKET in 1 BOX (0310-1105-30) / 5 g in 1 PACKET (0310-1105-01)
LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078	NDA	AstraZeneca Pharmaceuticals LP	0310-1105	0310-1105-39	11 PACKET in 1 BOX (0310-1105-39) / 5 g in 1 PACKET (0310-1105-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	FOR SUSPENSION;ORAL			Strength	5GM/PACKET
Approval Date:	May 18, 2018	TE:	AB	RLD:	Yes
Patent:	⤷ Start Trial	Patent Expiration:	Oct 14, 2035	Product Flag?		Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HYPERKALEMIA IN ADULTS
Patent:	⤷ Start Trial	Patent Expiration:	Feb 10, 2032	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF HYPERKALEMIA IN ADULTS
Patent:	⤷ Start Trial	Patent Expiration:	Feb 10, 2032	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF HYPERKALEMIA IN ADULTS

Expired US Patents for NDA 207078

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018	⤷ Start Trial	⤷ Start Trial
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.